These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20506513)

  • 1. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
    Shah AA; Rosen A; Hummers L; Wigley F; Casciola-Rosen L
    Arthritis Rheum; 2010 Sep; 62(9):2787-95. PubMed ID: 20506513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.
    Bunn CC; Denton CP; Shi-Wen X; Knight C; Black CM
    Br J Rheumatol; 1998 Jan; 37(1):15-20. PubMed ID: 9487245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
    Faucher B; Stein P; Granel B; Weiller PJ; Disdier P; Serratrice J; Harlé JR; Durand JM; Frances Y; Guis S; Pham T; Bardin N; Sanmarco M
    Eur J Intern Med; 2010 Apr; 21(2):114-7. PubMed ID: 20206882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
    Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
    Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.
    Yamasaki Y; Honkanen-Scott M; Hernandez L; Ikeda K; Barker T; Bubb MR; Narain S; Richards HB; Chan EK; Reeves WH; Satoh M
    Arthritis Rheum; 2006 Sep; 54(9):3051-6. PubMed ID: 16948135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies.
    Airo' P; Ceribelli A; Cavazzana I; Taraborelli M; Zingarelli S; Franceschini F
    J Rheumatol; 2011 Jul; 38(7):1329-34. PubMed ID: 21459934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
    Benyamine A; Bertin D; Heim X; Granel B; Bardin N
    Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
    [No Abstract]   [Full Text] [Related]  

  • 8. Serologic profile and mortality rates of scleroderma renal crisis in Italy.
    Codullo V; Cavazzana I; Bonino C; Alpini C; Cavagna L; Cozzi F; Del Papa N; Franceschini F; Guiducci S; Morozzi G; Ruffatti A; Ferri C; Giacomelli R; Matucci-Cerinic M; Valentini G; Montecucco C
    J Rheumatol; 2009 Jul; 36(7):1464-9. PubMed ID: 19487262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
    Shah AA; Hummers LK; Casciola-Rosen L; Visvanathan K; Rosen A; Wigley FM
    Arthritis Rheumatol; 2015 Apr; 67(4):1053-61. PubMed ID: 25605296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis.
    Saigusa R; Asano Y; Nakamura K; Miura S; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Noda S; Aozasa N; Akamata K; Sumida H; Miyazaki M; Tamaki Z; Yanaba K; Kuwano Y; Sato S
    J Dermatol; 2015 May; 42(5):524-7. PubMed ID: 25720827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
    Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
    Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma.
    Shah AA; Laiho M; Rosen A; Casciola-Rosen L
    Arthritis Rheumatol; 2019 Sep; 71(9):1571-1579. PubMed ID: 30888702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
    Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
    Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
    Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
    J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.
    Moinzadeh P; Fonseca C; Hellmich M; Shah AA; Chighizola C; Denton CP; Ong VH
    Arthritis Res Ther; 2014 Feb; 16(1):R53. PubMed ID: 24524733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
    D'Aoust J; Hudson M; Tatibouet S; Wick J; ; Mahler M; Baron M; Fritzler MJ
    Arthritis Rheumatol; 2014 Jun; 66(6):1608-15. PubMed ID: 24577935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
    Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
    Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis.
    Bonroy C; Van Praet J; Smith V; Van Steendam K; Mimori T; Deschepper E; Deforce D; Devreese K; De Keyser F
    J Immunol Methods; 2012 May; 379(1-2):53-60. PubMed ID: 22446156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting.
    Kuwana M
    J Nippon Med Sch; 2017; 84(2):56-63. PubMed ID: 28502960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study.
    Miyake M; Matsushita T; Takehara K; Hamaguchi Y
    Int J Rheum Dis; 2020 Aug; 23(9):1219-1225. PubMed ID: 32662135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.